US Patent Issued to Sarepta Therapeutics on Aug. 5 for "Exon skipping oligomer conjugates for muscular dystrophy" (Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,377,150, issued on Aug. 5, was assigned to Sarepta Therapeutics Inc. (Cambridge, Mass.).

"Exon skipping oligomer conjugates for muscular dystrophy" was invented by Marco A. Passini (Cambridge, Mass.) and Gunnar J. Hanson (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described."

The patent was filed on May 26, 2022, under Application No. 17/804,280.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml...